St Andrews Research Repository

St Andrews University Home
View Item 
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  • Login
JavaScript is disabled for your browser. Some features of this site may not work without it.

Irbesartan in Marfan syndrome (AIMS) : a double-blind, placebo-controlled randomised trial

Thumbnail
View/Open
Mullen_2019_Lancet_AIMS_CC.pdf (1.230Mb)
Date
21/12/2019
Author
Mullen, Michael
Jin, Xu Yu
Child, Anne
Stuart, A Graham
Dodd, Matthew
Aragon-Martin, José Antonio
Gaze, David
Kiotsekoglou, Anatoli
Yuan, Li
Hu, Jiangting
Foley, Claire
Van Dyck, Laura
Knight, Rosemary
Clayton, Tim
Swan, Lorna
Thomson, John D R
Erdem, Guliz
Crossman, David
Flather, Marcus
AIMS Investigators
Keywords
RC Internal medicine
E-DAS
BDC
R2C
~DC~
Metadata
Show full item record
Altmetrics Handle Statistics
Altmetrics DOI Statistics
Abstract
BACKGROUND: Irbesartan, a long acting selective angiotensin-1 receptor inhibitor, in Marfan syndrome might reduce aortic dilatation, which is associated with dissection and rupture. We aimed to determine the effects of irbesartan on the rate of aortic dilatation in children and adults with Marfan syndrome. METHODS: We did a placebo-controlled, double-blind randomised trial at 22 centres in the UK. Individuals aged 6-40 years with clinically confirmed Marfan syndrome were eligible for inclusion. Study participants were all given 75 mg open label irbesartan once daily, then randomly assigned to 150 mg of irbesartan (increased to 300 mg as tolerated) or matching placebo. Aortic diameter was measured by echocardiography at baseline and then annually. All images were analysed by a core laboratory blinded to treatment allocation. The primary endpoint was the rate of aortic root dilatation. This trial is registered with ISRCTN, number ISRCTN90011794. FINDINGS: Between March 14, 2012, and May 1, 2015, 192 participants were recruited and randomly assigned to irbesartan (n=104) or placebo (n=88), and all were followed for up to 5 years. Median age at recruitment was 18 years (IQR 12-28), 99 (52%) were female, mean blood pressure was 110/65 mm Hg (SDs 16 and 12), and 108 (56%) were taking β blockers. Mean baseline aortic root diameter was 34·4 mm in the irbesartan group (SD 5·8) and placebo group (5·5). The mean rate of aortic root dilatation was 0·53 mm per year (95% CI 0·39 to 0·67) in the irbesartan group compared with 0·74 mm per year (0·60 to 0·89) in the placebo group, with a difference in means of -0·22 mm per year (-0·41 to -0·02, p=0·030). The rate of change in aortic Z score was also reduced by irbesartan (difference in means -0·10 per year, 95% CI -0·19 to -0·01, p=0·035). Irbesartan was well tolerated with no observed differences in rates of serious adverse events. INTERPRETATION: Irbesartan is associated with a reduction in the rate of aortic dilatation in children and young adults with Marfan syndrome and could reduce the incidence of aortic complications.
Citation
Mullen , M , Jin , X Y , Child , A , Stuart , A G , Dodd , M , Aragon-Martin , J A , Gaze , D , Kiotsekoglou , A , Yuan , L , Hu , J , Foley , C , Van Dyck , L , Knight , R , Clayton , T , Swan , L , Thomson , J D R , Erdem , G , Crossman , D , Flather , M & AIMS Investigators 2019 , ' Irbesartan in Marfan syndrome (AIMS) : a double-blind, placebo-controlled randomised trial ' , Lancet , vol. 394 , no. 10216 , pp. 2263-2270 . https://doi.org/10.1016/S0140-6736(19)32518-8
Publication
Lancet
Status
Peer reviewed
DOI
https://doi.org/10.1016/S0140-6736(19)32518-8
ISSN
0140-6736
Type
Journal article
Rights
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Description
Funding: British Heart Foundation, the UK Marfan Trust, the UK Marfan Association.
Collections
  • University of St Andrews Research
URI
http://hdl.handle.net/10023/19148

Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.

Advanced Search

Browse

All of RepositoryCommunities & CollectionsBy Issue DateNamesTitlesSubjectsClassificationTypeFunderThis CollectionBy Issue DateNamesTitlesSubjectsClassificationTypeFunder

My Account

Login

Open Access

To find out how you can benefit from open access to research, see our library web pages and Open Access blog. For open access help contact: openaccess@st-andrews.ac.uk.

Accessibility

Read our Accessibility statement.

How to submit research papers

The full text of research papers can be submitted to the repository via Pure, the University's research information system. For help see our guide: How to deposit in Pure.

Electronic thesis deposit

Help with deposit.

Repository help

For repository help contact: Digital-Repository@st-andrews.ac.uk.

Give Feedback

Cookie policy

This site may use cookies. Please see Terms and Conditions.

Usage statistics

COUNTER-compliant statistics on downloads from the repository are available from the IRUS-UK Service. Contact us for information.

© University of St Andrews Library

University of St Andrews is a charity registered in Scotland, No SC013532.

  • Facebook
  • Twitter